IL324419A - A pharmaceutical preparation comprising 17-aag and staurosporine for use in the prevention or treatment of cancer and diseases resulting from excessive cell proliferation and a fatty polymer nanoparticle containing the compound - Google Patents

A pharmaceutical preparation comprising 17-aag and staurosporine for use in the prevention or treatment of cancer and diseases resulting from excessive cell proliferation and a fatty polymer nanoparticle containing the compound

Info

Publication number
IL324419A
IL324419A IL324419A IL32441925A IL324419A IL 324419 A IL324419 A IL 324419A IL 324419 A IL324419 A IL 324419A IL 32441925 A IL32441925 A IL 32441925A IL 324419 A IL324419 A IL 324419A
Authority
IL
Israel
Prior art keywords
staurosporine
concentration
17aag
zah
sdconcentration
Prior art date
Application number
IL324419A
Other languages
English (en)
Hebrew (he)
Inventor
Olga Swi?Ch
Rafa? MA?KIEWICZ
Weronika Piotrowska
Natalia ?Ab?D?
Mateusz Psurski
Joanna Wietrzyk
Wojciech Smoro?
Julia Witek
Original Assignee
Bs Biotechna Spo?Ka Akcyjna
Olga Swi?Ch
Rafa? MA?KIEWICZ
Weronika Piotrowska
Natalia ?Ab?D?
Mateusz Psurski
Joanna Wietrzyk
Wojciech Smoro?
Julia Witek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bs Biotechna Spo?Ka Akcyjna, Olga Swi?Ch, Rafa? MA?KIEWICZ, Weronika Piotrowska, Natalia ?Ab?D?, Mateusz Psurski, Joanna Wietrzyk, Wojciech Smoro?, Julia Witek filed Critical Bs Biotechna Spo?Ka Akcyjna
Publication of IL324419A publication Critical patent/IL324419A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
IL324419A 2023-05-03 2024-05-03 A pharmaceutical preparation comprising 17-aag and staurosporine for use in the prevention or treatment of cancer and diseases resulting from excessive cell proliferation and a fatty polymer nanoparticle containing the compound IL324419A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL444725A PL444725A1 (pl) 2023-05-03 2023-05-03 Kompozycja farmaceutyczna, stosowana w zapobieganiu lub leczeniu chorób nowotworowych i chorób wynikających z nadmiernej proliferacji komórek oraz nanocząsteczka polimerowo-lipidowa zawierająca kompozycję
PCT/PL2024/000021 WO2024228630A1 (en) 2023-05-03 2024-05-03 A pharmaceutical composition comprising 17-aag and staurosporine for use in the prevention or treatment of cancer and diseases resulting from excessive cell proliferation and a polymer- lipid nanoparticle containing the composition

Publications (1)

Publication Number Publication Date
IL324419A true IL324419A (en) 2026-01-01

Family

ID=91898976

Family Applications (1)

Application Number Title Priority Date Filing Date
IL324419A IL324419A (en) 2023-05-03 2024-05-03 A pharmaceutical preparation comprising 17-aag and staurosporine for use in the prevention or treatment of cancer and diseases resulting from excessive cell proliferation and a fatty polymer nanoparticle containing the compound

Country Status (5)

Country Link
EP (1) EP4704827A1 (pl)
CN (1) CN121419768A (pl)
IL (1) IL324419A (pl)
PL (1) PL444725A1 (pl)
WO (1) WO2024228630A1 (pl)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2180880A2 (en) * 2007-07-09 2010-05-05 Glen S. Kwon Micelle encapsulation of therapeutic agents
US10729692B2 (en) * 2017-02-26 2020-08-04 Institute For Cancer Research Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell death

Also Published As

Publication number Publication date
WO2024228630A1 (en) 2024-11-07
CN121419768A (zh) 2026-01-27
PL444725A1 (pl) 2024-11-04
EP4704827A1 (en) 2026-03-11

Similar Documents

Publication Publication Date Title
Kan et al. A liposomal formulation able to incorporate a high content of Paclitaxel and exert promising anticancer effect
Mu et al. Mixed micelles made of poly (ethylene glycol)–phosphatidylethanolamine conjugate and d-α-tocopheryl polyethylene glycol 1000 succinate as pharmaceutical nanocarriers for camptothecin
Hattori et al. Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors
Li et al. Albumin-stabilized layered double hydroxide nanoparticles synergized combination chemotherapy for colorectal cancer treatment
EP3603620A1 (en) Liposome composition and pharmaceutical composition
Chowdhury et al. Liposomes co-Loaded with 6-Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 3 (PFKFB3) shRNA Plasmid and Docetaxel for the Treatment of non-small Cell Lung Cancer: Chowdhury et al.
KR102653436B1 (ko) 암의 치료에서 사용하기 위한 리포솜 제형
CN109528654B (zh) 一种盐酸伊立替康和盐酸阿霉素共载脂质体及其制备方法
Cao et al. Lipid core-shell nanoparticles co-deliver FOLFOX regimen and siPD-L1 for synergistic targeted cancer treatment
CN108721643B (zh) 一种用于免疫化疗的pH敏感脂质体
Séhédic et al. Rapamycin-loaded lipid nanocapsules induce selective inhibition of the mTORC1-signaling pathway in glioblastoma cells
Mittal et al. Overcoming the challenges in the treatment of glioblastoma via nanocarrier-based drug delivery approach
Iqubal et al. A technical note on emerging combination approach involved in the onconanotherapeutics
Mohammad-Jafari et al. Cisplatin-based liposomal nanocarriers for drug delivery in lung cancer therapy: Recent progress and future outlooks
Mattern-Schain et al. Cell mimetic liposomal nanocarriers for tailored delivery of vascular therapeutics
He et al. Co-delivery liposomes of irinotecan hydrochloride and curcumin in the synergistic treatment of colorectal cancer
WO2024228630A1 (en) A pharmaceutical composition comprising 17-aag and staurosporine for use in the prevention or treatment of cancer and diseases resulting from excessive cell proliferation and a polymer- lipid nanoparticle containing the composition
CN105534904B (zh) 注射用多西他赛组合物及其制备方法
Fang et al. A progressively disassembled DNA repair inhibitors nanosystem for the treatment of BRCA wild-type triple-negative breast cancer
TW201825087A (zh) 胰臟癌治療
Padilla et al. MCT Nanoemulsions for the Efficient Delivery of siRNA
JP2026515210A (ja) がんおよび過度な細胞増殖に起因する疾患の予防または治療における使用のための、１７－ａａｇおよびスタウロスポリンを含む医薬組成物、ならびにその組成物を含有するポリマー脂質ナノ粒子
EP4704812A1 (en) A pharmaceutical composition comprising emetine and mitoxantrone for the prevention or treatment of mammary gland cancer and a liposome containing this composition
CZ2005796A3 (cs) Farmaceutická kompozice obsahující derivát taxanuse zlepsenou terapeutickou úcinností
JP2026515211A (ja) エメチンおよびミトキサントロンを含む、乳腺がんの予防または治療のための医薬組成物、ならびにこの組成物を含有するリポソーム